A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 183 participants.

Also called NCT01503736

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 183 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01503736
Main results
  • Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study Journal of nephrology, 2015-02 DOI, PubMed 24840781

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Countries
Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01503736. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2012-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease
Condition
Hyperphosphatemia
Condition
End Stage Renal Disease
Condition
ESRD
Intervention (Drug)
ferric citrate
Intervention (Drug)
ferric citrate
Intervention (Drug)
ferric citrate
Lead sponsor
Panion & BF Biotech Inc. (class: industry)

Record details

Record id
cardio:ct-nct01503736
Content hash
c09849ffe3bc584954237ede2177628ab0104c5578a5b7c6e8d5526efa8c8412